Home   >  
Epigenetics
  >  
Epigenetic Reader Domain

Classified by application

All Products

Signaling Pathways

Research Areas

Nature products

Antibodies

Peptides

Catalysts

Impurities

Intermediate

Raw Materials

Epigenetic Reader Domain

Chemical Structure Cat. No. Product Name CAS No.
VZ185 Chemical Structure
BCP38781 VZ185 2306193-61-1
VZ185 is an effective and selective dual BRD7/9 PROTAC degrader (DC50s: 4.5 and 1.8 nM, respectively).
VTP50469 fumarate Chemical Structure
BCP38003 VTP50469 fumarate 2169919-29-1
VTP50469 fumarate is a highly selective and orally active inhibitor of Menin-MLL interaction (Ki: 104 pM), and has potently anti-leukemia activity.
LP99 Chemical Structure
BCP38006 LP99 1808951-93-0
LP99 is the First Selective BRD7/9 Bromodomain Inhibitor.
GSK9311 Chemical Structure
BCP37781 GSK9311 1923851-49-3
GSK9311, a less active analogue of GSK6853, can be used as a negative control. GSK9311 inhibits BRPF bromodomain with pIC50 values of 6.0 and 4.3 for BRPF1 and BRPF2, respectively.
MS-402 Chemical Structure
BCP37770 MS-402 1672684-68-2
MS402 is a BD1-selective BET BrD inhibitor with Kis of 77 nM, 718 nM, 110 nM, 200 nM, 83 nM, and 240 nM for BRD4(BD1), BRD4(BD2), BRD3(BD1), BRD3(BD2), BRD2(BD1) and BRD2(BD2), respectively. MS402 blocks Th17 cell differentiation and ameliorates colitis in mice.
BAY1238097 Chemical Structure
BCP37705 BAY1238097 1564268-08-1
BAY1238097 is a potent and selective inhibitor of BET binding to histones and has strong anti-proliferative activity in different AML (acute myeloid leukemia) and MM (multiple myeloma) models through down-regulation of c-Myc levels and its downstream transcriptome (IC50 <100 nM).
PROTAC BET Degrader-10 Chemical Structure
BCP36816 PROTAC BET Degrader-10 1957234-97-7
PROTAC BET Degrader-10 is a potent BET protein BRD4 degrader extracted from patent WO2017007612A1, example 37, with a DC50 of 49 nM.
SNDX-5613 Chemical Structure
BCP36044 SNDX-5613 2169919-21-3
SNDX-5613 is a potent and specific Menin-MLL inhibitor. It can be used for the research of MLL-rearranged (MLL-r) acute leukemias, including acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML).
MI-463 Chemical Structure
BCP36072 MI-463 1628317-18-9
MI-463 is a highly potent and orally bioavailable small molecule inhibitor of the menin-mLL interaction.
MI-538 Chemical Structure
BCP36073 MI-538 1857417-10-7
MI-538 is an inhibitor of the interaction between menin and MLL fusion proteins with an IC50 of 21 nM.
123下一页末页共 116 条记录 1 / 12 页 
0086-13720134139